Prognostic Value of PtcO2 in Patients With COVID-19

NCT05682612 | Unknown

• 1 other identifier: 2023ZDSYLL001-P01
• Study Type: observational
• Target: 40
• Locations: 1 country
• Sites: 1

Brief Summary

Five percent of patients with COVID-19 progressed to respiratory failure and required ICU admission, such patients often have abnormal oxygen tolerance. However, there is still a lack of clinical indicators to predict the prognosis and treatment responsiveness of COVID-19.

Conditions

COVID-19 Acute Respiratory Distress Syndrome

Keywords

ARDS; respiratory failure; COVID-19

Outcome Measures

Primary Outcomes (1)

• Level of Transcutaneous partial pressure of oxygen

  Level of Transcutaneous partial pressure of oxygen

  up to 30 days

Secondary Outcomes (1)

• Level of Transcutaneous partial pressure of oxygen/FiO2

  up to 30 days

Study Arms (2)

Survivors

Survivors of COVID-19 induced respiratory failure

Other: outcome; Other: Subtype of COVID-19

Nonsurvivors

Nonsurvivors of COVID-19 induced respiratory failure

Other: outcome; Other: Subtype of COVID-19

Interventions

outcome OTHER

hospital survivors and nonsurvivors

Nonsurvivors; Survivors

Subtype of COVID-19 OTHER

Different subtype of COVID-19

Nonsurvivors; Survivors

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

COVID-19 patients

You may qualify if:

• Age: 18-80 years, male or female; Patients with COVID-9 pneumonia (typical imaging features of COVID-19 pneumonia) (oxygen saturation ≤ 93% during air or arterial partial pressure of oxygen (PaO2)/oxygen concentration (FiO2) ≤ 300 mmHg at rest)；

You may not qualify if:

• Pregnant or lactating women; Patients who refuse to undergo transcutaneous tissue oxygen pressure monitoring; Clinicians believe that patients are not appropriate; Patients undergoing ECMO.

Sponsors & Collaborators

• Southeast University, China: lead

Study Sites (1)

Zhongda hospital

Nanjing, Jiangsu, 210000, China

RECRUITING

MeSH Terms

Conditions

Respiratory Insufficiency; COVID-19

Condition Hierarchy (Ancestors)

Respiration Disorders; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases

Study Officials

• Jingyuan Xu, M.D.

  Southeast University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jingyuan Xu, M.D.

CONTACT

008613851417209; 13851417209@163.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: January 1, 2023
• First Posted: January 12, 2023
• Study Start: January 9, 2023
• Primary Completion: December 1, 2023
• Study Completion: December 30, 2023
• Last Updated: October 12, 2023

Record last verified: 2023-10

Locations

CN (1)